Duke to test bird flu vaccine dosing
A clinical trial to test different strengths of a vaccine designed to fight avian influenza will begin this month at Duke University Medical Center. The seven-month trial is spon...Hypertension lowered by Bedtime Dosing
Researchers in Japan have found that evening administration of the central alpha(2)-agonists guanabenz and clonidine effectively suppresses elevated blood pressure in the morning in hypertensive patients. The study was done on 133 patients with morning hypertension to receive once-daily evening administration of guanabenz or clonidine for four weeks. The blood pressure lowering effects of...Researchers chides parents for overdosing their kids
Australian parents seem to be pretty good at assuming the role of a doctor but pretty bad at administering medicine doses. Infact, a survey at the Queensland University// of Technology has revealed that nearly half of all Australian parents give their children an incorrect dose of medication, almost always higher than it should be. Over medication can have very serious repercussions es...RxDrugs: Drug Dosing Tool Special Mobile/Desktop Bundle
Description:Derived from the trusted, evidence-based AHFS Drug Information database, this continually updated tool provides dosing guidelines on thousands of commonly used brand and generic drugs and now includes nearly 400 integrated weight-based drug dosing calculators....ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
-- Genotypically Optimized Dosing Results in Improved Toleranceand Evidence of Anticancer Activity -- MELBOURNE, Australia, and MENLO PARK, California U.S.A. June 04,2007-ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announcedtoday the presentation of data from its Quinamed (amonafidedihydrochloride) phase 1/2a dose-escalation study, designed toidentify a genotypically optimis...ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun4, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP)announced today the presentation of data from its Quinamed(R)(amonafide dihydrochloride) phase 1/2a dose-escalation study,designed to identify a genotypically optimised dose of Quinamed inheavily pre-treated patients with a variety of solid tumors. Thekey outcomes f...